Annual Report

Overview

The report describes the company's strong 2019 operating performance, with operating income of RMB9,384.70 million and record profit growth. It highlights approximately RMB827.73 million of R&D investment across pharmaceutical, biologics, diagnostic, and API programs. The company and its wholly-owned and controlling subsidiaries employed 9,019 people at year-end. A dedicated Social Responsibility section covers targeted poverty alleviation, worker protections, safety, and environmental management.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2019
Period: 1 January 2019 – 31 December 2019
Publication date: 25 March 2020
Language: English
Pages
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services